pipette
ESEspañol

Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)

Leslie Cho, Stephen J Nicholls, Seth Frndak, Kathy Wolski, Børge Grønne Nordestgaard, Brian Manning, Eran Leitersdorf, Ulf Landmesser, Venu Menon, Jackie McCluskey, Michael Joseph Blaha, Ryuichi Morishita, Abraham Michael Lincoff, Ziqiang Zhao, Jing Wang, Raul Dias Santos, Ioanna Gouni‐Berthold, Sotirios Tsimikas, Anastasia Lesogor, Hui Cao, Steven E. Nissen

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
ConclusionsPelacarsen did not result in a lower risk of major adverse cardiovascular events than placebo at a median follow-up of 4.7 years.

Appeared: Monday, November 9. New England Journal of Medicine. Peer-reviewed journal.

DOI: 10.1056/nejmoa2610159